ECE2022 Eposter Presentations Endocrine-Related Cancer (61 abstracts)
Clinical characteristics and survival of a cohort of patients presenting with bone metastases from differentiated thyroid cancer
Ana Piñar Gutiérrez , Ana R. Romero Lluch , Suset Dueñ as Disotuar , Irene De Lara-Rodriguez & Elena Navarro
Virgen del Rocío University Hospital, Sevilla, Spain
Introduction: Bone metastases (BM) are rare in differentiated thyroid cancer (DTC). They determine the quality of life and survival of these patients. Our objective was to evaluate the characteristics, survival and prognostic factors of a cohort of patients with BM from CDT.
Methods: Retrospective descriptive study. Patients with BM from DTC diagnosed between 1980-2021 were included. Qualitative variables are shown as n(%); quantitative variables as median and interquartile range. Survival and prognostic factor analysis was performed using the Kaplan-Meier method and univariate tests.
Results: N=27. Women=17(63%). Follicular carcinoma=13(48%). Follow-up time (months)=72(34-222). Age at diagnosis=62(55-73). Exitus=18(66,7%). Suvival at 1 and 5 years was 68.5% and 43.5% respectively. No independent risk factors for increased risk of death were found.
| Variable | Result |
| BM diagnosis at initial evaluation | 13(48%) |
| BM diagnosis during follow-up | 14(52%) |
| Time until BM appearance (months) | 151(78-234) |
| Thyroglobulin at diagnosis, after thyroidectomy (ng/ml) | 1000(195-7743) |
| T | |
| 1-2 | 8(30%) |
| 3-4 | 14(51%) |
| N1 | 9(33%) |
| Multiple BM | 22(81,5%) |
| BM location | |
| Spine | 20(74%) |
| Pelvis | 10(37%) |
| Cranial | 5(18%) |
| Rib cage | 4(15%) |
| Upper limbs | 3(11%) |
| Lower limbs | 4(15%) |
| Metastases in other locations | 19(70,3%) |
| Skeleton-related events | |
| Bone fractures | 7(26%) |
| Spinal cord compression | 7(26%) |
| Pain | 10(37%) |
| Treatment with I131 | 19(70,4%) |
| I131 Uptake in BM | 10(37%) |
| Antiresorptive treatment | 10(37%) |
| BM Surgery | 4(15%) |
| Palliative radiation therapy | 9(33%) |
| Treatment with Tyrosine-kinase inhibitors | 7(26%) |
Conclusions: In our case series, 5-year survival was slightly lower than that reported in the scientific literature. This may be due to the fact that 48% presented with BM in the initial evaluation, although it has not been possible to prove it given the low number of cases. No other prognostic factors were found, possibly for the same reason.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more